PUBLISHER: The Business Research Company | PRODUCT CODE: 1948354
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948354
Transcatheter aortic valve replacement (TAVR), also referred to as transcatheter aortic valve implantation (TAVI), is a minimally invasive medical procedure utilized for the replacement of a diseased or dysfunctional aortic valve within the heart. This procedure is applicable to adults whose health is not robust enough for standard valve surgery.
The primary products associated with transcatheter aortic valve replacement include self-expandable transcatheter aortic valves, balloon-expandable transcatheter aortic valves, and mechanically expanded transcatheter aortic valves. Self-expandable transcatheter aortic valves serve as medical devices employed in the minimally invasive procedures known as transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve implantation (TAVI). These devices consist of materials for the valve frame and valve leaflet. Procedures such as transfemoral implantation, transapical implantation, and transaortic implantation can be conducted for conditions such as aortic stenosis, aortic regurgitation, among others. These procedures are carried out by hospitals, independent cardiac catheterization labs, ambulatory surgical centers, and other medical facilities.
Tariffs are impacting the transcatheter aortic valve replacement market by increasing costs of imported valve frames, bioprosthetic materials, delivery systems, and precision manufacturing equipment. Cardiac centers in North America and Europe are most affected due to reliance on imported high-value devices, while Asia-Pacific faces cost pressures in device assembly and distribution. These tariffs are raising procedure costs and affecting reimbursement dynamics. However, they are also encouraging localized valve manufacturing, regional clinical partnerships, and innovation in cost-optimized TAVR systems.
The transcatheter aortic valve replacement market research report is one of a series of new reports from The Business Research Company that provides transcatheter aortic valve replacement market statistics, including transcatheter aortic valve replacement industry global market size, regional shares, competitors with a transcatheter aortic valve replacement market share, detailed transcatheter aortic valve replacement market segments, market trends and opportunities, and any further data you may need to thrive in the transcatheter aortic valve replacement industry. This transcatheter aortic valve replacement market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The transcatheter aortic valve replacement market size has grown rapidly in recent years. It will grow from $5.87 billion in 2025 to $6.7 billion in 2026 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to rising prevalence of aortic stenosis, aging global population, increasing availability of cardiac catheterization labs, advancements in valve design materials, growing acceptance of minimally invasive cardiac procedures.
The transcatheter aortic valve replacement market size is expected to see rapid growth in the next few years. It will grow to $11.44 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing adoption of TAVR in intermediate-risk patients, rising demand for durable valve solutions, expansion of structural heart programs, growing integration of advanced imaging technologies, increasing focus on outpatient cardiac procedures. Major trends in the forecast period include increasing adoption of minimally invasive valve replacement procedures, rising use of self-expandable valve technologies, growing expansion into lower-risk patient groups, enhanced focus on procedural accuracy and imaging guidance, expansion of transfemoral access techniques.
The rising prevalence of aortic stenosis is a key factor driving the growth of the transcatheter aortic valve replacement (TAVR) market in the future. Aortic stenosis is a medical condition characterized by the narrowing of the aortic valve in the heart. TAVR offers a less invasive alternative to surgical aortic valve replacement (SAVR), helping to restore blood flow and alleviate the symptoms of aortic valve stenosis. For instance, in May 2024, data from the American Heart Association, a U.S.-based nonprofit organization, indicated that over 12% of older Americans are affected by aortic stenosis, a condition commonly seen in those over 65. If not treated, it can lead to heart failure and can be life-threatening. Additionally, a report published in March 2023 by the National Institute for Health and Care Excellence (NICE), a UK-based public organization, revealed that nearly 1.5% of individuals over 55 in the UK, or about 300,000 people, are living with severe aortic stenosis, with just under 200,000 experiencing symptomatic disease requiring treatment. This contributes to over 380,000 individuals on cardiac waiting lists by March 2023. Therefore, the increasing prevalence of aortic stenosis is driving the transcatheter aortic valve replacement market.
Leading companies in the transcatheter aortic valve replacement market are focusing on developing innovative solutions such as enhanced transcatheter valves to improve procedural access and clinical outcomes in aortic valve replacement. An enhanced transcatheter valve is a minimally invasive cardiac implant designed to replace a dysfunctional aortic valve while offering improved navigability, deployment control, and compatibility with diverse patient anatomies. For example, in March 2024, Medtronic plc, an Ireland-based healthcare technology company, launched the Evolut FX+ transcatheter aortic valve replacement system. The system features enlarged access windows in its frame design to enable smoother catheter movement and better access to coronary arteries across varied anatomies, while maintaining the hemodynamic performance and structural integrity of previous models, reinforcing its clinical utility for patients with symptomatic severe aortic stenosis.
In August 2024, Edwards Lifesciences, a US-based provider of structural heart therapies and transcatheter valve replacement technologies, acquired JC Medical for an undisclosed amount. Through this acquisition, Edwards aims to expand its transcatheter aortic valve replacement portfolio by adding advanced solutions for native aortic regurgitation and strengthening its position in next-generation structural heart interventions. JC Medical, also US-based, provides transcatheter aortic valve replacement devices.
Major companies operating in the transcatheter aortic valve replacement market are Abbott Laboratories Inc., Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Venus MedTech HangZhou Inc, Braile Biomedica, Peijia Medical Limited, Direct Flow Medical Inc., Transcatheter Technologies GmbH, Symetis SA, JenaValve Technology Inc., Micro Interventional Devices Inc., Xeltis BV, Tendyne Holdings Inc., MVRx Inc., Keystone Heart Ltd., Colibri Heart Valve LLC, HighLife SAS, Neovasc Inc., Aegis Surgical Limited, Foldax Inc., MValve Technologies Ltd., NaviGate Cardiac Structures Inc.
North America was the largest region in the transcatheter aortic valve replacement market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transcatheter aortic valve replacement market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the transcatheter aortic valve replacement market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transcatheter aortic valve replacement market consists of revenues earned by entities by providing services such as repairing the valve without removing the old damaged valve and placement of a heart valve into the body. The market value includes the value of related goods sold by the service provider or included within the service offering. The transcatheter aortic valve replacement market also includes sales of stainless steel stent, skirt and bovine pericardium leaflets, which are used in providing transcatheter aortic valve replacement services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transcatheter Aortic Valve Replacement Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses transcatheter aortic valve replacement market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for transcatheter aortic valve replacement ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transcatheter aortic valve replacement market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.